Építés alatt – nem éles oldal
Belépés
LeállítvaNo phase

A Study of Patients With Chronic Disease

Megadott ok: Sponsor decision to terminate study

Key facts

Where
Ann Arbor, Clearwater, Colorado Springs, Louisville és New Bern, Egyesült ÁllamokSee the 5 sites

Where in Egyesült Államok

  • University of Michigan Allergy Specialty Clinic & Food AllergyAnn Arbor, Egyesült ÁllamokNo longer taking part
  • St Francis Medical InstituteClearwater, Egyesült ÁllamokNo longer taking part
  • Asthma and Allergy Associates, PCColorado Springs, Egyesült ÁllamokNo longer taking part
  • Family Allergy & Asthma Research InstitutionLouisville, Egyesült ÁllamokNo longer taking part
  • Coastal Carolina Healthcare, P.A.New Bern, Egyesült ÁllamokNo longer taking part

Trial details

Who runs it
Target PharmaSolutions, Inc.
Trial code
NCT04263727
Record updated
2025. április 3.
Original description
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared study infrastructure supports progressive development of the registry across the spectrum of chronic diseases.Read full original descriptionShow less

A Longitudinal Observational Study of Patients With Chronic Disease

TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared study infrastructure supports progressive development of the registry across the spectrum of chronic diseases.

Inclusion: Adults and children being managed or treated for a chronic disease under study. Diagnosis is based on the clinical judgement of the care provider; Patient is anticipated to have continued management of their chronic disease at the participating site.

Exclusion: Inability to provide informed assent/consent.

ClinicalTrials.gov NCT04263727